BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person ImmuneBD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune

BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry

2025/12/18 20:15
4 min read

BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study

FRANKLIN LAKES, N.J., Dec. 18, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, to advance research in deep human immune profiling and support the development of immune-mediated therapies.

The collaboration includes developing and validating a high-parameter flow cytometry panel that can capture key functional pathways in whole blood, including phosphorylation markers, which provide powerful insight into how single cells respond to drugs or disease states. The panel will support a planned 1,000-patient immune profiling study, in partnership with the Penn Colton Center for Autoimmunity, expected to start this summer. The project will leverage the BD FACSDiscover™ A8 Cell Analyzer, BD Rhapsody™ System, BD reagents, software and informatics, with BD teams managing reagents, instrumentation, and spectral data algorithms, and I3H teams serving as scientific and clinical leads. The team intends to publish a peer-reviewed manuscript describing the results of the study.

“This project demonstrates the power of collaboration between academia and industry,” said Dr. E. John Wherry, PhD, the Richard and Barbara Schiffrin President’s Distinguished Professor, director of the Institute for Immunology and Immune Health at the University of Pennsylvania, and the director of the Colton Consortium for Autoimmunity. “We are bringing together cross-functional experts to transform human immune profiling for maximum impact, enabling deeper insights from our immune cells that could accelerate development of precise medical treatments.”

The collaboration reflects a shared vision of unlocking the power of the human immune system to advance science and health. It is made possible by the BD FACSDiscover™ A8 Cell Analyzer, which is the first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, and the new BD Horizon™ Chroma solution for dried high-parameter panels. The project supports the commitment of both organizations to contribute to the research community through collaboration and knowledge sharing.

“High-parameter single-cell studies of this kind, once considered infeasible, are increasingly becoming central to better understanding the human immune system,” said Steve Conly, worldwide president of BD Biosciences. “Our ecosystem of industry-leading BD flow cytometers, single-cell systems, reagents, software and informatics, provide a critical missing puzzle piece that can support the important work of organizations like I3H to translate and deliver immunological insights into quantitative, actionable information for discovery and clinical care teams around the world.”

More information is available at bdbiosciences.com.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:

Media:

Investors:

Fallon McLoughlin

Adam Reiffe

Director, Public Relations

VP, Investor Relations

201.258.0361

201.847.6927

fallon.mcloughlin@bd.com

adam.reiffe@bd.com

Media for Penn Medicine:

Eric Horvath

Associate News Director

Penn Medicine

215-821-4289

Eric.horvath@pennmedicine.upenn.edu

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-penn-institute-for-immunology-and-immune-health-collaborate-to-advance-immunotherapy-through-flow-cytometry-302645260.html

SOURCE BD (Becton, Dickinson and Company)

Market Opportunity
FLOW Logo
FLOW Price(FLOW)
$0,03544
$0,03544$0,03544
-%4,65
USD
FLOW (FLOW) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Exploring Market Buzz: Unique Opportunities in Cryptocurrencies

Exploring Market Buzz: Unique Opportunities in Cryptocurrencies

In the ever-evolving world of cryptocurrencies, recent developments have sparked significant interest. A closer look at pricing forecasts for Cardano (ADA) and rumors surrounding a Solana (SOL) ETF, coupled with the emergence of a promising new entrant, Layer Brett, reveals a complex market dynamic. Cardano's Prospects: A Closer Look Cardano, a stalwart in the blockchain space, continues to hold its ground with its research-driven development strategy. The latest price predictions for ADA suggest potential gains, predicting a double or even quadruple increase in its valuation. Despite these optimistic forecasts, the allure of exponential gains drives traders toward more speculative ventures. The Buzz Around Solana ETF The potential introduction of a Solana ETF has the crypto community abuzz, potentially catapulting SOL prices to new heights. As investors await regulatory decisions, the impact of such an ETF on Solana's value could be substantial, potentially reaching up to $300. However, as with Cardano, the substantial market capitalization of Solana may temper its growth potential. Why Layer Brett is Gaining Traction Amidst established names, a new contender, Layer Brett, has started to capture the market's attention with its early presale stages. Offering a low entry price of just $0.0058 and promising over 700% in staking rewards, Layer Brett presents a tempting proposition for those looking to maximize returns. Comparative Analysis: ADA, SOL, and $LBRETT While both ADA and SOL offer stable investment choices with reliable growth, Layer Brett emerges as a high-risk, high-reward option that could potentially offer significantly higher returns due to its nascent market position and aggressive economic model. Initial presale pricing lets investors get in on the ground floor. Staking rewards currently exceed 690%, a persuasive incentive for early adopters. Backed by Ethereum's Layer 2 for enhanced transaction speed and reduced costs. A community-focused $1 million giveaway to further drive engagement and investor interest. Predicted by some analysts to offer up to 50x returns in coming years. Shifting Sands: Investor Movements As the crypto market landscape shifts, many investors, including those traditionally holding ADA and SOL, are beginning to diversify their portfolios by turning to high-potential opportunities like Layer Brett. The combination of strategic presale pricing and significant staking rewards is creating a momentum of its own. Act Fast: Time-Sensitive Opportunities As September progresses, opportunities to capitalize on these low entry points and high yield offerings from Layer Brett are likely to diminish. With increasing attention and funds being directed towards this new asset, the window to act is closing quickly. Invest in Layer Brett now to secure your position before the next price hike and staking rewards reduction. For more information, visit the Layer Brett website, join their Telegram group, or follow them on X by clicking the following links: Website Telegram X Disclaimer: This is a sponsored press release and is for informational purposes only. It does not reflect the views of Bitzo, nor is it intended to be used as legal, tax, investment, or financial advice.
Share
Coinstats2025/09/18 18:39
Tests 50-day EMA barrier near 183.00

Tests 50-day EMA barrier near 183.00

The post Tests 50-day EMA barrier near 183.00 appeared on BitcoinEthereumNews.com. EUR/JPY remains steady after three days of gains, trading around 182.70 during
Share
BitcoinEthereumNews2026/02/23 17:03
Moonshot MAGAX vs Shiba Inu: The AI-Powered Meme-to-Earn Revolution Challenging a Meme Coin Giant

Moonshot MAGAX vs Shiba Inu: The AI-Powered Meme-to-Earn Revolution Challenging a Meme Coin Giant

Discover how Moonshot MAGAX’s AI-powered meme-to-earn platform outpaces Shiba Inu with innovative tokenomics and growth potential in 2025.
Share
Blockchainreporter2025/09/18 03:15